Azenta, Inc. Form 10-Q Summary
Business Context and Reporting Period
Azenta, formerly Brooks Automation, reported results for the three months ended December 31, 2021, its fiscal 2022 first quarter. The continuing business provides life sciences sample management, automated storage, genomic services, cold-chain solutions, and related products. Results were restated to present the semiconductor automation business as discontinued operations.
- Reportable segments: Life Sciences Products and Life Sciences Services.
- The company changed its name to Azenta, Inc. and began trading under the symbol AZTA on December 1, 2021.
- The semiconductor automation business was sold to Thomas H. Lee Partners on February 1, 2022, after the quarter ended, for $3.0 billion in cash, subject to customary adjustments. Expected net proceeds were approximately $2.4 billion.
Financial Performance and Key Metrics
| Metric | Q1 FY2022 | Q1 FY2021 | Change |
|---|---|---|---|
| Continuing operations revenue | $139.7 million | $118.1 million | 18% |
| Gross profit | $67.0 million | $57.3 million | 17% |
| Gross margin | 48.0% | 48.5% | Down 0.5 percentage points |
| Operating income (loss) | $(0.3) million | $0.4 million | Declined $0.7 million |
| Income from continuing operations | $2.9 million | $2.7 million | Up $0.2 million |
| Income from discontinued operations | $40.5 million | $23.3 million | Up $17.1 million |
| Net income | $43.3 million | $26.0 million | Up $17.3 million |
| Diluted earnings per share | $0.58 | $0.35 | Up $0.23 |
- Life Sciences Products revenue increased 10% to $49.9 million; adjusted operating income was $4.4 million and adjusted margin was approximately 9%.
- Life Sciences Services revenue increased 24% to $89.8 million; adjusted operating income was $7.9 million and adjusted margin was approximately 9%.
- Product gross margin rose to 45.5% from 45.1%, while Services gross margin declined to 49.4% from 50.7%.
- Research and development expense increased 28% to $6.5 million. Selling, general and administrative expense increased 17% to $60.7 million.
- The $4.7 million income tax benefit was primarily attributable to a $4.8 million discrete stock-compensation tax windfall.
- Foreign currency losses contributed to other expense of $1.1 million, compared with other income of $1.3 million in the prior-year period.
Cash Flow, Liquidity, Debt and Balance Sheet
- Net cash provided by operating activities was $15.6 million, compared with $43.7 million in the prior-year quarter. The decline primarily reflected increased inventory and prepaid expenses.
- Capital expenditures were $18.4 million, including $9.9 million for the China facility. Net cash used in investing activities was $18.4 million.
- Cash used in financing activities was $7.7 million, primarily reflecting $7.5 million of dividends, or $0.10 per share.
- Total cash, cash equivalents and restricted cash declined to $273.0 million from $285.3 million at September 30, 2021. Excluding $45.0 million classified within assets held for sale, cash, restricted cash and marketable securities were $231.8 million.
- At December 31, 2021, the company had $49.7 million of term debt, no borrowings under its $75.0 million revolving credit facility, and was in compliance with applicable covenants.
- On February 1, 2022, the company used $50.0 million of sale proceeds to repay the term loan and terminated the revolving credit facility.
- Total assets were $1.85 billion and stockholders’ equity was $1.37 billion at December 31, 2021.
Material Changes, Outlook and Risks
- Management expects the divestiture to materially transform the company into a focused life sciences business. No formal revenue or earnings guidance is provided in the filing.
- Management stated that it expects adequate resources to satisfy working capital, debt service, financing and capital expenditure requirements for the next twelve months.
- Management estimated that COVID-19 had a positive net impact of approximately $10 million on continuing-operations revenue in both reported quarters. Future effects remain uncertain because of variants, vaccine effectiveness, supply-chain constraints, employee outbreaks and changes in research-related demand.
- Revenue growth was supported by higher demand for automated storage, sample repository services, next-generation sequencing and gene synthesis. Services margins were pressured by higher employee and laboratory costs.
- The filing identifies supply-chain disruption, customer demand, competition, tariffs and export controls, foreign currency movements, international operations, key-personnel retention and regulatory compliance as significant risks.
- The company recorded a $7.6 million liability for potential tariffs related to GENEWIZ imports. It expects no significant penalties but intends to pay tariffs ultimately determined to be owed.
- Non-cancellable commitments totaled $59.9 million, including $44.0 million for inventory purchases and $14.2 million for information-technology commitments. Letters of credit totaled approximately $1.3 million.
- The company disclosed ordinary-course legal proceedings and indemnification matters but did not believe they would materially affect financial condition or results of operations.
- Approximately $1.0 billion of sale proceeds was held in euros after the divestiture, creating increased foreign-exchange and potential repatriation risks.
Most Important Facts for Investors to Verify
- Confirm the final cash proceeds, working-capital adjustments, taxes and accounting gain from the semiconductor automation sale.
- Assess how the post-divestiture balance sheet and capital-allocation plans affect liquidity, dividends, acquisitions and share repurchases.
- Separate recurring life sciences operating performance from discontinued-operation income and the one-time stock-compensation tax benefit.
- Monitor Services gross-margin recovery, supply-chain conditions, China facility spending and COVID-19-related demand.
- Review foreign-currency exposure, including the euro-denominated sale proceeds and the sensitivity of earnings to exchange-rate changes.
- Track the GENEWIZ tariff liability, outstanding commitments, legal contingencies and future tax effects of the divestiture.